hb0043
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 19, 2025 (NCT06895499)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
- Interleukin-36 gammaINHIBITOR
IL36G inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06999083 | Phase 1 | Jun 3, 2025 | New Zealand Clinical Research, Zhejiang Huahai Pharmaceutical Co., Ltd. |
| NCT06895499 | Phase 1/Phase 2 (Phase 2) | Mar 19, 2025 | Shandong first medical University, Zhejiang Huahai Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 2 | 2025 |
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2025 |
| Shandong first medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1